In accordance with the decision of the Chairman of the Egyptian Drug Authority (EDA) No. 450 of 2023, and in light of the EDA’s commitment to maintaining communication with pharmaceutical companies, encouraging investment, and promoting the principle of equal opportunity among companies—and based on the directive of the Chairman of the EDA dated July 16, 2025—the following proposal has been approved:

"Companies subject to the third case of Decision No. 450 of 2023 issued by the Chairman of the Egyptian Drug Authority—Pathways (C) and (D)—are permitted to continue the registration of the entitled number of human medicinal products after August 10, 2025, provided that the approved service fee, as endorsed by the Chairman of the EDA on March 21, 2024, is paid."